

Attorney Docket No.: KUZ0030US.NP  
Inventors: Toshimitsu et al.  
Serial No.: 10/577,746  
Filing Date: April 27, 2006  
Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

**Listing of the claims:**

Claim 1 (currently amended): A transdermal preparation used for administration of pergolide or a pharmaceutically acceptable salt thereof, said preparation having an adhesive layer containing 9-50 mass% comprising pergolide and/or a pharmaceutically acceptable salt thereof in an adhesive layer containing and 10-70 mass% styrene-isoprene-styrene block copolymer, wherein said preparation is capable of achieving a plasma AUC ratio of pergolide or the pharmaceutically acceptable salt thereof to at least one metabolite thereof of 1:0.5 to 1:5, wherein the ratio (A/B) of the maximum plasma level (A) of pergolide and/or the pharmaceutically acceptable salt thereof to a plasma level (B) thereof in the next administration is less than 2.

Claim 2 (original): The transdermal preparation according to claim 1, wherein the plasma AUC ratio of pergolide and/or a pharmaceutically acceptable salt thereof to at least one metabolite thereof is 1:0.5 to 1:3.5.

Claim 3 (original): The transdermal preparation according to claim 2, wherein the plasma AUC ratio of pergolide and/or a pharmaceutically acceptable salt thereof to at least one metabolite thereof is 1:0.5 to 1:2.

Claim 4 (previously presented): The transdermal preparation according to claim 1, wherein the metabolite is one or more kinds comprising pergolide sulfoxide, pergolide

Attorney Docket No.: **KUZ0030US.NP**  
Inventors: **Toshimitsu et al.**  
Serial No.: **10/577,746**  
Filing Date: **April 27, 2006**  
Page 3

sulfone, despropyl pergolide or despropyl pergolide sulfoxide.

Claim 5 (original): The transdermal preparation according to claim 4, wherein the metabolite is pergolide sulfoxide.

Claim 6 (previously presented): The transdermal preparation according to claim 1, wherein the pharmaceutically acceptable salt is one or more kinds comprising hydrochloride, sulfate, mesylate, citrate, fumarate, tartarate, maleate or acetate.

Claim 7 (original): The transdermal preparation according to claim 6, wherein the pharmaceutically acceptable salt is mesylate.

Claim 8 (canceled)

Claim 9 (currently amended): The transdermal preparation according to claim 1, wherein the adhesive layer contains further comprises a (meth)acrylic acid copolymer.

Claim 10 (currently amended): The transdermal preparation according to claim 9, wherein the adhesive layer further contains comprises an acrylic polymer, said acrylic polymer being different from the (meth)acrylic acid copolymer.

Claim 11 (canceled)

Attorney Docket No.: **KUZ0030US.NP**  
Inventors: **Toshimitsu et al.**  
Serial No.: **10/577,746**  
Filing Date: **April 27, 2006**  
Page 4

Claim 12 (previously presented): The transdermal preparation according to claim 1, wherein said preparation is an adhesive patch.

Claim 13 (withdrawn): A method of reducing a side effect caused by administration of a transdermal preparation containing pergolide and/or a pharmaceutically acceptable salt thereof in an adhesive layer, wherein said preparation is capable of achieving a plasma AUC ratio of pergolide or the pharmaceutically acceptable salt thereof to at least one metabolite thereof of 1:0.5 to 1:5, thereby reducing the side effect.

Claim 14 (withdrawn): The method according to claim 13, wherein the plasma AUC ratio of pergolide and/or the pharmaceutically acceptable salt thereof to at least one metabolite thereof is 1:0.5 to 1:3.5.

Claim 15 (withdrawn): The method according to claim 14, wherein the plasma AUC ratio of pergolide and/or the pharmaceutically acceptable salt thereof to at least one metabolite thereof is 1:0.5 to 1:2.

Claim 16 (withdrawn): The method according to claim 13, wherein the metabolite is one or more kinds comprising pergolide sulfoxide, pergolide sulfone, despropyl pergolide or despropyl pergolide sulfoxide.

Claim 17 (withdrawn): The method according to claim 16, wherein the metabolite is pergolide sulfoxide.

Attorney Docket No.: **KUZ0030US.NP**  
Inventors: **Toshimitsu et al.**  
Serial No.: **10/577,746**  
Filing Date: **April 27, 2006**  
Page 5

Claim 18 (withdrawn): The method according to claim 13, wherein the pharmaceutically acceptable salt is one or more kinds comprising hydrochloride, sulfate, mesylate, citrate, fumarate, tartarate, maleate or acetate.

Claim 19 (withdrawn): The method according to claim 18, wherein the pharmaceutically acceptable salt is mesylate.

Claim 20 (withdrawn): The method according to claim 13, wherein the ratio (A/B) of the maximum plasma level (A) of pergolide and/or the pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration and/or the ratio (A'/B') of the maximum plasma level (A') of pergolide sulfoxide to the plasma level (B') of pergolide sulfoxide in the next administration is less than 2.

Claim 21 (withdrawn): The method according to claim 13, wherein the adhesive layer contains a (meth)acrylic acid copolymer.

Claim 22 (withdrawn): The method according to claim 21, wherein the adhesive layer further contains an acrylic polymer, the acrylic polymer being different from the (meth)acrylic acid copolymer.